Abstract 543P
Background
Interstitial pneumonia (IP) is the common and poor prognostic comorbidities in patients with non-small cell lung cancer (NSCLC) and is a known risk factor for immune checkpoint inhibitor (ICI)-induced pneumonitis. The aim of this study is to assess the incidence, severity and risk factors for pneumonitis induced by immune checkpoint inhibitor (ICI) monotherapy in NSCLC patients with idiopathic IP.
Methods
This is a multicenter, retrospective study in patients with (1) advanced or recurrent NSCLC, (2) comorbid idiopathic IP, and (3) receiving ICI monotherapy as second-line or later therapy. All CTs at baseline and at the onset of pneumonitis were centrally adjudicated by a board-certified radiologist. We performed logistic regression analysis to identify risk factors for pneumonitis using clinical characteristics, laboratory data and radiological findings as variables.
Results
Sixty-five patients were analyzed, with a median age of 71 years, and 98.5% had a smoking history. Sixty percent received nivolumab, 21.5% received atezolizumab and 18.5% received pembrolizumab. The median cycle of ICI was 4 cycles. Radiological patterns of IP were UIP (11%), probable UIP (15%), indeterminate for UIP (51%), alternative (23%), respectively, with 23% having honeycomb lung and a median %FVC of 95%. The incidence of pneumonitis was 23.1% for all grade and 13.9% for ≥grade3. We could not identify any significant risk factors for ICI-induced pneumonitis in the multivariate logistic regression analysis. There was no difference in the incidence and severity of ICI-induced pneumonitis when comparing patients with and without honeycomb lung, or with FVC ≥80% and <80%.
Conclusions
There was no difference in the risk of ICI-induced pneumonitis according to specific findings, including the radiological pattern of comorbid IP, the presence of honeycomb lung, and pulmonary function tests. ICIs should be carefully administrated in NSCLC with any types of comorbid IP.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
S. Ikeda: Financial Interests, Personal, Advisory Board: AstraZeneca, Chugai, Ono, Daiichi Sankyo; Financial Interests, Personal, Invited Speaker: AstraZeneca, Chugai, Ono, Bristol Myers Squibb, Taiho, Eli Lilly, Pfizer, Boehringer Ingelheim, Takeda; Financial Interests, Personal, Research Grant: AstraZeneca, Chugai. J. Sakakibara-Konishi: Financial Interests, Personal, Research Grant: eli Lilly. K. Yokoo: Financial Interests, Personal, Invited Speaker: AstraZeneca, Chugai, Eli Lilly, Kyowa Kirin, MerckBiopharma, Novartis, Terumo, Takeda, Nippon Kayaku, Bristol Myers Squibb. T. Iwasawa: Financial Interests, Personal, Advisory Board: CANON Medical Systems, Ziosoft I; Financial Interests, Personal, Invited Speaker: Boehringer Ingelheim. T. Misumi: Financial Interests, Personal, Invited Speaker: Miyarisan. T. Ogura: Financial Interests, Personal, Invited Speaker: Japanese Boehringer Ingelheim, Shionogi; Financial Interests, Personal, Advisory Board: BMS, Japanese Boehringer Ingelheim, Taiho, Shionogi. All other authors have declared no conflicts of interest.
Resources from the same session
571P - Dacomitinib in treatment-naïve EGFR-mutant NSCLC patients with multiple brain metastases: Initial efficacy and safety data from a phase II study
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
572P - Multivariable five-year survival prediction model for prognosing patients with EGFR-mutated NSCLC treated with EGFR-TKIs
Presenter: Qi-An Wang
Session: Poster Display
Resources:
Abstract
573P - LUMINATE-103: Real-world treatment patterns and outcomes of patients (pts) with epidermal growth factor receptor mutant (EGFR MU), non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC): Pooled analysis of large US electronic health record (EHR) datasets
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
574P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutations
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
575P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: A multicenter cohort study
Presenter: Puyuan Xing
Session: Poster Display
Resources:
Abstract
576P - Clonality of both EGFR and co-occurring TP53 mutations affect the treatment efficacy of the third-generation EGFR-TKIs in advanced-stage EGFR-mutant non-small cell lung cancer
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
577P - A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC
Presenter: Daeho Choi
Session: Poster Display
Resources:
Abstract
578P - Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute retrospective study
Presenter: Ling-Jen Hung
Session: Poster Display
Resources:
Abstract
579P - Real-world study of dacomitinib as first-line treatment for patients with EGFR-mutant non-small cell lung cancer
Presenter: Ji Eun Shin
Session: Poster Display
Resources:
Abstract
580P - Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor <italic>(EGFR)</italic> 21L858R mutation: A multicenter, ambispective, consecutive case-series study
Presenter: Shouzheng Wang
Session: Poster Display
Resources:
Abstract